BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/12/2024 3:55:58 PM | Browse: 226 | Download: 586
 |
Received |
|
2024-02-27 10:11 |
|
Peer-Review Started |
|
2024-02-27 10:11 |
|
First Decision by Editorial Office Director |
|
2024-04-17 03:28 |
|
Return for Revision |
|
2024-04-17 03:28 |
|
Revised |
|
2024-04-18 00:29 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-04-29 03:03 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-04-29 05:40 |
|
Articles in Press |
|
2024-04-29 05:40 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-06-19 09:40 |
|
Publish the Manuscript Online |
|
2024-07-12 15:55 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Meer M Chisthi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Meer M Chisthi, MBBS, MS, Professor, Surgeon, Department of General Surgery, Government Medical College Pathanamthitta, Aanakuthi, Konni 689691, Kerala, India. meerchisthi@gmail.com |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Lenvatinib; Programmed cell death protein-1 inhibitors; Unresectable hepatocellular carcinoma |
| Core Tip |
Transarterial chemoembolization (TACE) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors presents an encouraging therapeutic approach for unresectable hepatocellular carcinoma (HCC). This triple therapy demonstrates well-tolerated outcomes with a median overall survival of 26.43 mo and a median progression-free survival of 10.07 month. Notably, patients with Barcelona Clinic Liver Cancer B-stage, exhibiting early neutrophil-to-lymphocyte ratio and alpha-fetoprotein responses, show superior clinical outcomes. Understanding these predictive factors can guide treatment decisions and enhance the efficacy of TACE/lenvatinib/PD-1 therapy in unresectable HCC. |
| Publish Date |
2024-07-12 15:55 |
| Citation |
Chisthi MM. Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(7): 2884-2887
|
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i7/2884.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i7.2884 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
